NYRADA CDI
Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance
Nyrada reports strong preclinical Xolatryp efficacy in liver cancer and a US patent allowance, highlighting a ~39% boost vs doxorubicin alone.
Nyrada Confirms Xolatryp Offers Mitochondrial Stabilisation after Traumatic Brain Injury
Nyrada (ASX: NYR) has confirmed its small molecule therapy Xolatryp can reduce mitochondrial calcium ion loading in the brain following traumatic injury. A collaborative study with the University of New South Wales and the Walter Reed Army Institute of Research sought to evaluate the efficacy of Xolatryp in a penetrating traumatic brain injury (TBI) rodent […]
Weekly wrap: rumours of wars send the ASX 200 tumbling
It is the Bible that talks about not being alarmed by “wars and rumours of wars” but Australian share market investors weren’t quite so sanguine, pushing down the ASX 200 sharply. By the close of trade on Friday 55.2 points or 0.7% had been erased from the ASX 200 as the reality of a worsening […]
Nyrada’s NYR-BI03 shows significant cardioprotective efficacy in preclinical study
A preclinical rat study using Nyrada’s (ASX: NYR) lead drug candidate NYR-BI03 has demonstrated up to 86% efficacy in limiting cardiovascular damage associated with coronary heart disease following acute myocardial ischaemic-reperfusion injury. The findings are believed to position NYR-BI03 as a novel cardioprotective treatment following myocardial infarction, which is a leading cause of morbidity and […]